Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is a strong investment opportunity due to its promising pipeline candidates and potential for approvals in both the US and EU markets for its lead candidate apitegromab. The recent resubmission of the BLA and positive regulatory interactions provide key de-risking events, while the company's early-stage programs and strategic positioning in the muscle-directed space offer long-term growth potential. KOL feedback and alignment with patient-experienced unmet needs support a strong launch and broad applicability of apitegromab in treating SMA. Risks to achieving our price target include clinical, regulatory, competitive, and financial risks, but the company's potential to become a multi-blockbuster therapy in SMA makes it worth considering for investment.

Bears say

Scholar Rock Holding is facing challenges in gaining market acceptance due to the crowded and competitive market for spinal muscular atrophy treatments. Furthermore, its limited product portfolio and lack of revenue could lead to financial strain, especially if its clinical trials for its pipeline candidates do not yield positive results. Additionally, the company may face regulatory challenges and delays in obtaining approval, further hampering its potential for growth and profitability.

SRRK has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 13 analysts, SRRK has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.